Lamotrigine is NOT appropriate for treating premature ventricular contractions in a 16-year-old male
Lamotrigine should not be used for PVCs, as it is an antiepileptic medication with emerging evidence of proarrhythmic effects, not an antiarrhythmic agent. The question appears to reflect a fundamental misunderstanding—lamotrigine treats seizures, not cardiac arrhythmias.
Critical Safety Concern
Recent evidence demonstrates that lamotrigine may actually promote ventricular arrhythmias rather than treat them. A 2025 murine study showed lamotrigine caused reentrant ventricular tachycardia in 78% of hearts tested (7/9), preferentially slowing longitudinal conduction velocity and creating a functional substrate for dangerous reentrant circuits 1. This directly contradicts any potential use for treating PVCs.
The FDA issued a 2021 safety warning about lamotrigine use in patients with underlying cardiac disorders, based on concerns about its cardiac effects 2. A subsequent 2025 retrospective cohort study of 53,652 patients found no significant increase in ventricular arrhythmias compared to levetiracetam, but this does not establish efficacy for treating arrhythmias—only that it may not cause them in all patients 2.
Appropriate Management of PVCs in This Patient
For a 16-year-old with PVCs and no structural heart disease:
First-line approach:
- Beta-blockers are the standard first-line pharmacologic option for symptomatic PVCs 3
- Nondihydropyridine calcium channel blockers (verapamil, diltiazem) are alternative first-line agents 3
- Many adolescents with isolated PVCs and no structural disease require only reassurance and lifestyle modification 3
If pharmacologic therapy is needed and first-line agents fail:
- Class IC antiarrhythmics like flecainide may be considered for PVCs originating from the ventricular outflow tract in structurally normal hearts 4
- Flecainide at clinically relevant concentrations showed uniform conduction slowing without the preferential longitudinal effects seen with lamotrigine 1
Catheter ablation should be considered for:
- High PVC burden (>10-15%)
- PVC-induced cardiomyopathy
- Refractory symptomatic PVCs despite medical therapy 3
Why This Matters
The use of lamotrigine for cardiac arrhythmias represents a dangerous medication error. Lamotrigine's FDA-approved indications are epilepsy and bipolar disorder 5. Its dosing in adolescents for epilepsy typically starts at 25 mg daily with slow titration 6, 7, but these doses are irrelevant for PVCs because lamotrigine should never be prescribed for this indication.
If this patient has both epilepsy and PVCs, lamotrigine can still be used for seizure control (the 2025 study found no increased arrhythmia risk in real-world use 2), but a separate appropriate antiarrhythmic strategy must address the PVCs. The caution about using trazodone "with caution in patients with premature ventricular contractions" 8 reflects general principles of avoiding medications that may exacerbate arrhythmias, which would apply to any proarrhythmic agent.